The endometriosis market was valued at valued at $1,239.81 million in 2021, and is projected to reach $3,926.41 million by 2031, registering a CAGR of 12.6% from 2022 to 2031.
Endometriosis is a type of disease in which endometrial tissue grows outside the uterus. Endometriosis is defined as a condition where tissue similar to the lining of the uterus is found outside of the uterine cavity such as on the ovaries, fallopian tubes, or other pelvic structures. Endometriosis are of four types. These include superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Endometriosis can lead to pain during periods, excessive bleeding, painful urination, frequent bowel movements, constipation, severe pain during sexual intercourse, chronic pelvic pain, and abdominal bloating. Endometriosis can cause infertility and increase the risk of ovarian cancer.
There is currently no cure for endometriosis, however pain associated with endometriosis can be managed with medication. The gonadotropin-releasing hormone (GnRH) medicines such as Lupron Depot (leuprolide), Synarel (nafarelin), Zoladex (goserelin) and oral contraceptive such as Provera (medroxyprogesterone), Sprintec (ethinyl estradiol) are used for the management of endometriosis.
Major factors driving growth of the endometriosis market include rise in demand for novel drugs and hormonal therapies, rise in awareness regarding early disease diagnosis and treatment of endometriosis among global population and increasing availability of advanced diagnostic methods such as biopsy, ultrasound and rise in the prevalence of endometriosis. For instance, according to the world health organization (WHO) 2021 report, about 190 million reproductive-age females have endometriosis, accounting for about 10% of the female population globally.
Furthermore, the healthcare business is projected to witness growth, owing to a rise in advancement in drug delivery technologies, rise in research regarding using combination of drug for the management of endometriosis drives the growth of endometriosis market. For instance, in January 2022, according to pharmaceutical technology, two GnRH antagonists, ObsEva’s Yselty (linzagolix) and Myovant Sciences/Pfizer’s Relugolix combination tablet, are set to launch across the seven major pharmaceutical markets, the US, five major European markets (France, Germany, Italy, Spain, and the UK) and Japan, in the next two years. Relugolix will launch in Japan first, entering that market in 2022. These medications will be the first GnRH antagonists launched in the five major European markets and Japan, which will bolster the endometriosis market significantly.
However, the high cost of medicine and low diagnostic rate is expected to hamper the growth of the endometriosis market. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for endometriosis medicine manufacturers worldwide in the future.
Moreover, rapidly advancing global healthcare infrastructure, rise in awareness regarding female reproductive health, increasing government initiatives to raise awareness about women’s health in developing countries like India, China drives the growth of endometriosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period. In addition, a rise in R&D investments in discovery & development of effective medicine, rise in funding from government for research regarding treatment of endometriosis and significant rise in capital income in developed countries drives the growth of the market. For instance, in March 2022, the U.S. federal government announced $92 million funds to National Institute of Child Health and Human Development (NICHD) and continues to provide $370 million to the Department of Defense’s Peer-Reviewed Medical Research Program (PRMRP) for endometriosis research.
Furthermore, the rise in key strategies include product launch, partnership, product approval, collaboration, merger, acquisition adopted by key players strengthen demand of medication for the management of endometriosis in the market. For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need. Hence, such factors drive the growth of the endometriosis market.
The endometriosis market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is classified into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). On the basis of treatment, the market is classified into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. Depending on the distribution channel, it is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Consilient Health Limited, GlaxoSmithKline plc, Merck & Co. Inc, Pfizer Inc, Sanofi India Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Ltd.
Endometriosis is a type of disease in which endometrial tissue grows outside the uterus. Endometriosis is defined as a condition where tissue similar to the lining of the uterus is found outside of the uterine cavity such as on the ovaries, fallopian tubes, or other pelvic structures. Endometriosis are of four types. These include superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Endometriosis can lead to pain during periods, excessive bleeding, painful urination, frequent bowel movements, constipation, severe pain during sexual intercourse, chronic pelvic pain, and abdominal bloating. Endometriosis can cause infertility and increase the risk of ovarian cancer.
There is currently no cure for endometriosis, however pain associated with endometriosis can be managed with medication. The gonadotropin-releasing hormone (GnRH) medicines such as Lupron Depot (leuprolide), Synarel (nafarelin), Zoladex (goserelin) and oral contraceptive such as Provera (medroxyprogesterone), Sprintec (ethinyl estradiol) are used for the management of endometriosis.
Major factors driving growth of the endometriosis market include rise in demand for novel drugs and hormonal therapies, rise in awareness regarding early disease diagnosis and treatment of endometriosis among global population and increasing availability of advanced diagnostic methods such as biopsy, ultrasound and rise in the prevalence of endometriosis. For instance, according to the world health organization (WHO) 2021 report, about 190 million reproductive-age females have endometriosis, accounting for about 10% of the female population globally.
Furthermore, the healthcare business is projected to witness growth, owing to a rise in advancement in drug delivery technologies, rise in research regarding using combination of drug for the management of endometriosis drives the growth of endometriosis market. For instance, in January 2022, according to pharmaceutical technology, two GnRH antagonists, ObsEva’s Yselty (linzagolix) and Myovant Sciences/Pfizer’s Relugolix combination tablet, are set to launch across the seven major pharmaceutical markets, the US, five major European markets (France, Germany, Italy, Spain, and the UK) and Japan, in the next two years. Relugolix will launch in Japan first, entering that market in 2022. These medications will be the first GnRH antagonists launched in the five major European markets and Japan, which will bolster the endometriosis market significantly.
However, the high cost of medicine and low diagnostic rate is expected to hamper the growth of the endometriosis market. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for endometriosis medicine manufacturers worldwide in the future.
Moreover, rapidly advancing global healthcare infrastructure, rise in awareness regarding female reproductive health, increasing government initiatives to raise awareness about women’s health in developing countries like India, China drives the growth of endometriosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period. In addition, a rise in R&D investments in discovery & development of effective medicine, rise in funding from government for research regarding treatment of endometriosis and significant rise in capital income in developed countries drives the growth of the market. For instance, in March 2022, the U.S. federal government announced $92 million funds to National Institute of Child Health and Human Development (NICHD) and continues to provide $370 million to the Department of Defense’s Peer-Reviewed Medical Research Program (PRMRP) for endometriosis research.
Furthermore, the rise in key strategies include product launch, partnership, product approval, collaboration, merger, acquisition adopted by key players strengthen demand of medication for the management of endometriosis in the market. For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need. Hence, such factors drive the growth of the endometriosis market.
The endometriosis market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is classified into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). On the basis of treatment, the market is classified into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. Depending on the distribution channel, it is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Consilient Health Limited, GlaxoSmithKline plc, Merck & Co. Inc, Pfizer Inc, Sanofi India Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the endometriosis market analysis from 2021 to 2031 to identify the prevailing endometriosis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the endometriosis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global endometriosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Superficial peritoneal lesion
- Endometriomas
- Others
By Distribution channel
- Hospital pharmacy
- Online pharmacy
- Retail pharmacy
By Treatment
- Oral contraceptives
- Gonadotropin-releasing hormone (GnRH) medicines
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Consilient Health Limited
- Serum Institute of India Pvt. Ltd.
- Abbott Laboratories
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Pfizer Inc.
- AstraZeneca plc
- Abbvie Inc
- Sanofi
- Sun Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd
- Teva Pharmaceutical Industries Limited
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in funding for research of endometriosis
3.4.1.2. Rise in awareness regarding endometriosis
3.4.2. Restraints
3.4.2.1. High cost of endometriosis medicine
3.4.3. Opportunities
3.4.3.1. Rise in R&D activities and recent product approval
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ENDOMETRIOSIS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Superficial peritoneal lesion
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Endometriomas
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: ENDOMETRIOSIS MARKET, BY TREATMENT
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral contraceptives
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Gonadotropin-releasing hormone (GnRH) medicines
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacy
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online pharmacy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Retail pharmacy
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ENDOMETRIOSIS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Treatment
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Treatment
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Treatment
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Treatment
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Treatment
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Treatment
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Treatment
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Treatment
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Treatment
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Treatment
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Treatment
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Treatment
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Treatment
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Treatment
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Treatment
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Treatment
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Treatment
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Treatment
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Treatment
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Treatment
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Treatment
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Type
7.5.5.3.3. Market size and forecast, by Treatment
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Type
7.5.5.4.3. Market size and forecast, by Treatment
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Consilient Health Limited
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.3. GlaxoSmithKline plc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Merck & Co. Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Pfizer Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Sanofi
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Serum Institute of India Pvt. Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Sun Pharmaceutical Industries Ltd
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Torrent Pharmaceuticals Ltd
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.11. Abbvie Inc
9.11.1. Company overview
9.11.2. Key Executives
9.11.3. Company snapshot
9.11.4. Operating business segments
9.11.5. Product portfolio
9.11.6. Business performance
9.12. AstraZeneca plc
9.12.1. Company overview
9.12.2. Key Executives
9.12.3. Company snapshot
9.12.4. Operating business segments
9.12.5. Product portfolio
9.12.6. Business performance
List of Tables
Table 01. Global Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 02. Endometriosis Market for Superficial Peritoneal Lesion, by Region, 2021-2031 (Revenue, $Million)
Table 03. Endometriosis Market for Endometriomas, by Region, 2021-2031 (Revenue, $Million)
Table 04. Endometriosis Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 05. Global Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 06. Endometriosis Market for Oral Contraceptives, by Region, 2021-2031 (Revenue, $Million)
Table 07. Endometriosis Market for Gonadotropin-Releasing Hormone (Gnrh) Medicines, by Region, 2021-2031 (Revenue, $Million)
Table 08. Endometriosis Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 09. Global Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 10. Endometriosis Market for Hospital Pharmacy, by Region, 2021-2031 (Revenue, $Million)
Table 11. Endometriosis Market for Online Pharmacy, by Region, 2021-2031 (Revenue, $Million)
Table 12. Endometriosis Market for Retail Pharmacy, by Region, 2021-2031 (Revenue, $Million)
Table 13. Endometriosis Market, by Region, 2021-2031 (Revenue, $Million)
Table 14. North America Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 15. North America Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 16. North America Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 17. North America Endometriosis Market, by Country, 2021-2031 (Revenue, $Million)
Table 18. U.S. Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 19. U.S. Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 20. U.S. Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 21. Canada Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 22. Canada Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 23. Canada Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 24. Mexico Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 25. Mexico Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 26. Mexico Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 27. Europe Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 28. Europe Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 29. Europe Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 30. Europe Endometriosis Market, by Country, 2021-2031 (Revenue, $Million)
Table 31. Germany Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 32. Germany Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 33. Germany Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 34. France Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 35. France Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 36. France Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 37. UK Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 38. UK Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 39. UK Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 40. Italy Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 41. Italy Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 42. Italy Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 43. Spain Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 44. Spain Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 45. Spain Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 46. Rest of Europe Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 49. Asia-Pacific Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Endometriosis Market, by Country, 2021-2031 (Revenue, $Million)
Table 53. China Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 54. China Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 55. China Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. Japan Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 57. Japan Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 58. Japan Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 59. India Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 60. India Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 61. India Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 62. Australia Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 63. Australia Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 64. Australia Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 65. South Korea Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 66. South Korea Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 67. South Korea Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 68. Rest of Asia-Pacific Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 70. Rest of Asia-Pacific Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 71. LAMEA Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 74. LAMEA Endometriosis Market, by Country, 2021-2031 (Revenue, $Million)
Table 75. Brazil Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 76. Brazil Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 77. Brazil Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 78. Saudi Arabia Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 80. Saudi Arabia Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 81. South Africa Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 82. South Africa Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 83. South Africa Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 84. Rest of LAMEA Endometriosis Market, by Type, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Endometriosis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 86. Rest of LAMEA Endometriosis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 87. Abbott Laboratories: Key Executives
Table 88. Abbott Laboratories: Company Snapshot
Table 89. Abbott Laboratories: Product Segments
Table 90. Abbott Laboratories: Product Portfolio
Table 91. Consilient Health Limited: Key Executives
Table 92. Consilient Health Limited: Company Snapshot
Table 93. Consilient Health Limited: Product Segments
Table 94. Consilient Health Limited: Product Portfolio
Table 95. GlaxoSmithKline plc: Key Executives
Table 96. GlaxoSmithKline plc: Company Snapshot
Table 97. GlaxoSmithKline plc: Product Segments
Table 98. GlaxoSmithKline plc: Product Portfolio
Table 99. GlaxoSmithKline plc: Key Stratergies
Table 100. Merck & Co. Inc.: Key Executives
Table 101. Merck & Co. Inc.: Company Snapshot
Table 102. Merck & Co. Inc.: Product Segments
Table 103. Merck & Co. Inc.: Product Portfolio
Table 104. Pfizer Inc.: Key Executives
Table 105. Pfizer Inc.: Company Snapshot
Table 106. Pfizer Inc.: Product Segments
Table 107. Pfizer Inc.: Product Portfolio
Table 108. Sanofi: Key Executives
Table 109. Sanofi: Company Snapshot
Table 110. Sanofi: Product Segments
Table 111. Sanofi: Product Portfolio
Table 112. Serum Institute of India Pvt. Ltd.: Key Executives
Table 113. Serum Institute of India Pvt. Ltd.: Company Snapshot
Table 114. Serum Institute of India Pvt. Ltd.: Product Segments
Table 115. Serum Institute of India Pvt. Ltd.: Product Portfolio
Table 116. Sun Pharmaceutical Industries Ltd: Key Executives
Table 117. Sun Pharmaceutical Industries Ltd: Company Snapshot
Table 118. Sun Pharmaceutical Industries Ltd: Product Segments
Table 119. Sun Pharmaceutical Industries Ltd: Product Portfolio
Table 120. Teva Pharmaceutical Industries Limited: Key Executives
Table 121. Teva Pharmaceutical Industries Limited: Company Snapshot
Table 122. Teva Pharmaceutical Industries Limited: Service Segments
Table 123. Teva Pharmaceutical Industries Limited: Product Portfolio
Table 124. Torrent Pharmaceuticals Ltd: Key Executives
Table 125. Torrent Pharmaceuticals Ltd: Company Snapshot
Table 126. Torrent Pharmaceuticals Ltd: Product Segments
Table 127. Torrent Pharmaceuticals Ltd: Product Portfolio
Table 128. Abbvie Inc: Key Executives
Table 129. Abbvie Inc: Company Snapshot
Table 130. Abbvie Inc: Product Segments
Table 131. Abbvie Inc: Product Portfolio
Table 132. Astrazeneca plc: Key Executives
Table 133. Astrazeneca plc: Company Snapshot
Table 134. Astrazeneca plc: Product Segments
Table 135. Astrazeneca plc: Product Portfolio
List of Figures
Figure 01. Endometriosis Market, 2021-2031
Figure 02. Segmentation of Endometriosis Market, 2021-2031
Figure 03. Top Investment Pockets in Endometriosis Market (2022-2031)
Figure 04. Moderate Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalendometriosis Market
Figure 10. Endometriosis Market, by Type, 2021 (%)
Figure 11. Comparative Share Analysis of Endometriosis Market for Superficial Peritoneal Lesion, by Country 2021-2031 (%)
Figure 12. Comparative Share Analysis of Endometriosis Market for Endometriomas, by Country 2021-2031 (%)
Figure 13. Comparative Share Analysis of Endometriosis Market for Others, by Country 2021-2031 (%)
Figure 14. Endometriosis Market, by Treatment, 2021 (%)
Figure 15. Comparative Share Analysis of Endometriosis Market for Oral Contraceptives, by Country 2021-2031 (%)
Figure 16. Comparative Share Analysis of Endometriosis Market for Gonadotropin-Releasing Hormone (Gnrh) Medicines, by Country 2021-2031 (%)
Figure 17. Comparative Share Analysis of Endometriosis Market for Others, by Country 2021-2031 (%)
Figure 18. Endometriosis Market, by Distribution Channel, 2021 (%)
Figure 19. Comparative Share Analysis of Endometriosis Market for Hospital Pharmacy, by Country 2021-2031 (%)
Figure 20. Comparative Share Analysis of Endometriosis Market for Online Pharmacy, by Country 2021-2031 (%)
Figure 21. Comparative Share Analysis of Endometriosis Market for Retail Pharmacy, by Country 2021-2031 (%)
Figure 22. Endometriosis Market by Region, 2021
Figure 23. U.S. Endometriosis Market, 2021-2031 ($Million)
Figure 24. Canada Endometriosis Market, 2021-2031 ($Million)
Figure 25. Mexico Endometriosis Market, 2021-2031 ($Million)
Figure 26. Germany Endometriosis Market, 2021-2031 ($Million)
Figure 27. France Endometriosis Market, 2021-2031 ($Million)
Figure 28. UK Endometriosis Market, 2021-2031 ($Million)
Figure 29. Italy Endometriosis Market, 2021-2031 ($Million)
Figure 30. Spain Endometriosis Market, 2021-2031 ($Million)
Figure 31. Rest of Europe Endometriosis Market, 2021-2031 ($Million)
Figure 32. China Endometriosis Market, 2021-2031 ($Million)
Figure 33. Japan Endometriosis Market, 2021-2031 ($Million)
Figure 34. India Endometriosis Market, 2021-2031 ($Million)
Figure 35. Australia Endometriosis Market, 2021-2031 ($Million)
Figure 36. South Korea Endometriosis Market, 2021-2031 ($Million)
Figure 37. Rest of Asia-Pacific Endometriosis Market, 2021-2031 ($Million)
Figure 38. Brazil Endometriosis Market, 2021-2031 ($Million)
Figure 39. Saudi Arabia Endometriosis Market, 2021-2031 ($Million)
Figure 40. South Africa Endometriosis Market, 2021-2031 ($Million)
Figure 41. Rest of LAMEA Endometriosis Market, 2021-2031 ($Million)
Figure 42. Top Winning Strategies, by Year
Figure 43. Top Winning Strategies, by Development
Figure 44. Top Winning Strategies, by Company
Figure 45. Product Mapping of Top 10 Players
Figure 46. Competitive Dashboard
Figure 47. Competitive Heatmap: Endometriosis Market
Figure 48. Top Player Positioning, 2021
Figure 49. Abbott Laboratories: Net Sales, 2019-2021 ($Million)
Figure 50. Abbott Laboratories: Revenue Share by Segment, 2021 (%)
Figure 51. Abbott Laboratories: Revenue Share by Region, 2021 (%)
Figure 52. GlaxoSmithKline plc: Net Sales, 2019-2021 ($Million)
Figure 53. GlaxoSmithKline plc: Revenue Share by Segment, 2021 (%)
Figure 54. GlaxoSmithKline plc: Revenue Share by Region, 2021 (%)
Figure 55. Merck & Co. Inc.: Net Sales, 2019-2021 ($Million)
Figure 56. Merck & Co. Inc.: Revenue Share by Segment, 2021 (%)
Figure 57. Merck & Co. Inc.: Revenue Share by Region, 2021 (%)
Figure 58. Pfizer Inc.: Net Revenue, 2019-2021 ($Million)
Figure 59. Pfizer Inc.: Revenue Share by Segment, 2021 (%)
Figure 60. Pfizer Inc.: Revenue Share by Region, 2021 (%)
Figure 61. Sanofi: Net Revenue, 2019-2021 ($Million)
Figure 62. Sanofi: Research & Development Expenditure, 2019-2021
Figure 63. Sanofi: Revenue Share by Segment, 2021 (%)
Figure 64. Sanofi: Revenue Share by Region, 2021 (%)
Figure 65. Sun Pharmaceutical Industries Ltd: Net Revenue, 2019-2021 ($Million)
Figure 66. Sun Pharmaceutical Industries Ltd: Revenue Share by Region, 2021 (%)
Figure 67. Teva Pharmaceutical Industries Limited: Net Revenue, 2019-2021 ($Million)
Figure 68. Teva Pharmaceutical Industries Limited: Revenue Share by Segment, 2021 (%)
Figure 69. Torrent Pharmaceuticals Ltd: Net Revenue, 2019-2021 ($Million)
Figure 70. Torrent Pharmaceuticals Ltd: Revenue Share by Region, 2021 (%)
Figure 71. Abbvie Inc: Net Revenue, 2019-2021 ($Million)
Figure 72. Abbvie Inc: Revenue Share by Segment, 2021 (%)
Figure 73. Abbvie Inc: Revenue Share by Region, 2021 (%)
Figure 74. Astrazeneca plc: Net Revenue, 2019-2021 ($Million)
Figure 75. Astrazeneca plc: Revenue Share by Segment, 2021 (%)
Figure 76. Astrazeneca plc: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, “Endometriosis Market," The endometriosis market was valued at $1.2 billion in 2021, and is estimated to reach $3.9 billion by 2031, growing at a CAGR of 12.6% from 2022 to 2031.Endometriosis is a type of disease in which endometrial cells grow outside the uterus. Endometriosis are of four types including superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Endometriosis mostly occurs in ovaries.
Endometriosis is a condition in which an endometrium-type tissue grows outside of the uterus such as ovaries, fallopian tubes, and tissue around the uterus and ovaries. Endometriosis is grouped into four types on the basis of affected area of pelvis or abdomen i.e., superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. This report includes revenues generated from treatments that are used for endometriosis. However, this report excluded the revenue generated from endometriosis services and volume data.
Key factors driving the growth of the endometriosis market include a rise in prevalence of endometriosis, rise in awareness regarding endometriosis led to high adoption of endometriosis treatment. Moreover, growth in funding for research of endometriosis, growing awareness regarding female reproductive health, rise in endometriosis research propel the demand for endometriosis treatment and boost the growth of endometriosis market.
The market also offers growth opportunities to the key players in the market. Increase in R&D investments and launch of novel products for the treatment of endometriosis have gained high traction in the last 5 years. The growth of such platforms is further accelerated by the increase in government initiatives to create awareness regarding endometriosis. As a result, the key players engaged in the pharmaceutical industry have invested in R&D for the discovery of new endometriosis treatment are expected to gain high traction and provide lucrative opportunity for the growth of endometriosis market.
Furthermore, shift in focus of key players toward care of female reproductive health, increment in number of formation of alliance for increasing awareness regarding endometriosis drives the growth of endometriosis market. For instance, in November 2020, seven women’s health-focused organizations include the American College of Obstetricians and Gynecologists (ACOG), the Endometriosis Association, AbbVie, HealthyWomen, the International Pelvic Pain Society (IPPS), GE Healthcare and Black Women’s Health Imperative (BWHI) announced the formation of the Alliance for Endometriosis to improve the lives of the one in 10 women of reproductive age living with this disease in the U.S. The aim of Alliance for Endometriosis is to eliminate stigma and encourage more open and productive conversations that lead to faster diagnoses and improved treatment options and experiences in endometriosis.
The endometriosis market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is classified into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). On the basis of treatment, the market is classified into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. Depending on the distribution channel, it is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Artelon, Arthrex, Inc., Corin Group, Enovis, Exactech, Inc., FX-Global Inc., Group FH Communication, Integra Lifesciences, Neoligaments, Stryker Corporation. The players in the market have been actively engaged in the adoption various strategies such as product launch to remain competitive and gain advantage over the competitors in the market. For instance, in September 2021, Striker has launched its Citrelock tendon fixation devices system for orthopedic surgical applications. The new system provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen, that has unique chemical and mechanical properties for orthopaedic surgical applications. The launch of Citrelock will help the company to strengthen its orthopedics portfolio.
Key Market Insights
- On the basis of type, the superficial peritoneal lesion segment was the highest revenue contributor to the market in 2021 and is estimated to reach $2485.74 million by 2031 and is expected to be the fastest-growing segment with a CAGR of 12.8% during the forecast period.
- Based on treatment, the oral contraceptives segment generated maximum revenue in 2021 and gonadotropin-releasing hormone (Gn
- RH) medicines segment is expected to witness highest CAGR of 13.1% during the forecast period.
- Based on end user, the hospital pharmacy segment was the highest revenue contributor to the market in 2021. However, the online pharmacy segment is estimated to be the fastest-growing segment with a CAGR of 13.0% during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 14.3% during the forecast period.
Companies Mentioned
- Consilient Health Limited
- Serum Institute of India Pvt. Ltd.
- Abbott Laboratories
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Pfizer Inc.
- AstraZeneca plc
- Abbvie Inc
- Sanofi
- Sun Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd
- Teva Pharmaceutical Industries Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 220 |
| Published | December 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1239.81 million |
| Forecasted Market Value ( USD | $ 3926.41 million |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
